Comparative Pharmacology
Head-to-head clinical analysis: LUVOX versus PAXIL CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUVOX versus PAXIL CR.
LUVOX vs PAXIL CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.
None Documented
None Documented
Clinical Note
moderateFluvoxamine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Desmopressin
"The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin."
Clinical Note
moderateFluvoxamine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Clotrimazole
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
The terminal elimination half-life of paroxetine (PAXIL CR) is approximately 15-20 hours. This supports once-daily dosing and requires about 5-7 days to reach steady-state concentration.
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Renal excretion accounts for approximately 64% of the administered dose, with 2% as unchanged parent drug and the remainder as metabolites. Fecal excretion accounts for about 36%, mostly as metabolites. Less than 1% is excreted in bile.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant
"The metabolism of Clotrimazole can be decreased when combined with Fluvoxamine."